Arvinas, Inc. presented new preclinical data for its investigational PROTAC BCL6 degrader, ARV-393, at the European Hematology Association (EHA) 2025 Congress. The data highlighted ARV-393's significant single-agent activity in patient-derived xenograft (PDX) models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL), and transformed follicular lymphoma (tFL).
In combination with oral small molecule inhibitors, ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL). These findings suggest broad utility for ARV-393 across non-Hodgkin lymphoma subtypes.
The preclinical data provides a compelling rationale for considering combination strategies, including chemotherapy-free approaches, to develop new therapeutic options for adult patients with lymphoma. ARV-393 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.